3-rx.comCustomer Support
3-rx.com
   
HomeAbout UsFAQContactHelp
News Center
Health Centers
Medical Encyclopedia
Drugs & Medications
Diseases & Conditions
Medical Symptoms
Med. Tests & Exams
Surgery & Procedures
Injuries & Wounds
Diet & Nutrition
Special Topics



\"$alt_text\"');"); } else { echo"\"$alt_text\""; } ?>


Join our Mailing List





Syndicate

You are here : 3-RX.com > Home > Cancer - Breast Cancer -

2 views are better than 1 in 3-D breast screening

Cancer • • Breast CancerApr 18, 13

One view 3D breast screening (tomosynthesis) means less radiation dose and about five seconds less compression, but a study from Yale University, New Haven, CT, found that obtaining both views is necessary to help ensure that a cancer won’t be missed.

There are practices in Europe that have reported performing only a single view, specifically the mediolateral oblique (MLO) view, said Dr. Noa Beck, the lead author of the study. Two views are standard in the U.S. for 3D breast screening; “we wanted to see if one view would be sufficient,” she said. Seven breast imagers reviewed 164 cancers visualized with tomosynthesis and noted on what views the cancers could be seen. The study found that 56% of cancers were equally well seen on both the MLO view and the craniocaudal (CC) view; 34% of the cancers were either better or only seen on the CC view, said Dr. Beck. “The CC view achieves better compression, and this likely explains the reason the CC view showed lesions more clearly. In a few cases, lesions were only seen on the MLO view because of where the cancers were located in the breast,” she said.

The study results emphasize that “obtaining both views is necessary to ensure that a cancer will be optimally visualized,” said Dr. Beck.

Dr. Beck will present her study at the ARRS annual meeting on April 19 in Washington, DC.

###

Samantha Schmidt
.(JavaScript must be enabled to view this email address)
703-858-4316
American Roentgen Ray Society



Print Version
Tell-a-Friend
comments powered by Disqus

RELATED ARTICLES:
  New biomarkers may influence drug design and alternative treatments of cancer, study shows
  Metabolic profiles distinguish early stage ovarian cancer with unprecedented accuracy
  Moffitt researchers develop first genetic test to predict tumor sensitivity to radiation therapy
  New drug for neuroblastoma shows promise in phase I study
  Experimental treatment sends deadly leukemia into remission
  Study could reduce unnecessary cancer screening
  UA researchers discover component of cinnamon prevents colorectal cancer in mice
  Profiling approach to enable right lung cancer treatment match
  Fat grafting technique improves results of breast augmentation
  Germline TP53 mutations in patients with early-onset colorectal cancer
  Clinical trial suggests combination therapy is best for low-grade brain tumors
  UW research shows sensor technology may help improve accuracy of clinical breast exams

 












Home | About Us | FAQ | Contact | Advertising Policy | Privacy Policy | Bookmark Site